146 related articles for article (PubMed ID: 2003987)
21. Determination of tumor marker levels in cystic fluid of benign liver cysts.
Iwase K; Takenaka H; Oshima S; Yagura A; Nishimura Y; Yoshidome K; Tanaka T
Dig Dis Sci; 1992 Nov; 37(11):1648-54. PubMed ID: 1385056
[TBL] [Abstract][Full Text] [Related]
22. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
23. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
[TBL] [Abstract][Full Text] [Related]
24. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Int J Pancreatol; 1987; 2(5-6):349-60. PubMed ID: 3320227
[TBL] [Abstract][Full Text] [Related]
25. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma.
Metzgar RS; Rodriguez N; Finn OJ; Lan MS; Daasch VN; Fernsten PD; Meyers WC; Sindelar WF; Sandler RS; Seigler HF
Proc Natl Acad Sci U S A; 1984 Aug; 81(16):5242-6. PubMed ID: 6591188
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
27. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
[TBL] [Abstract][Full Text] [Related]
28. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma.
Tempero M; Takasaki H; Uchida E; Takiyama Y; Colcher D; Metzgar RS; Pour PM
Am J Surg Pathol; 1989; 13 Suppl 1():89-95. PubMed ID: 2699170
[TBL] [Abstract][Full Text] [Related]
29. Factors affecting serum levels of CA 19-9 with special reference to benign hepatobiliary and pancreatic diseases.
Sawabu N; Takemori Y; Toya D; Yoneshima M; Kidani H; Satomura Y; Ohta H; Hattori N
Gastroenterol Jpn; 1986 Oct; 21(5):491-8. PubMed ID: 3465664
[TBL] [Abstract][Full Text] [Related]
30. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
[TBL] [Abstract][Full Text] [Related]
31. The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.
Toshkov I; Mogaki M; Kazakoff K; Pour PM
Int J Pancreatol; 1994 Apr; 15(2):97-103. PubMed ID: 8071575
[TBL] [Abstract][Full Text] [Related]
32. Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumour spread, liver impairment, and age.
Basso D; Fabris C; Del Favero G; Angonese C; Meggiato T; Infantino A; Plebani M; Piccoli A; Leandro G; Burlina A
Dis Markers; 1988; 6(3):203-7. PubMed ID: 3168400
[TBL] [Abstract][Full Text] [Related]
33. Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
Basso D; Fabris C; Del Favero G; Panucci A; Plebani M; Angonese C; Leandro G; Dodi G; Burlina A; Naccarato R
Oncology; 1988; 45(1):24-9. PubMed ID: 3422390
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
[TBL] [Abstract][Full Text] [Related]
35. Expression of CA19-9, DU-PAN-2, and SPan-1 antigens on two types of normal salivary mucins.
Ho JJ; Norton K; Chung YS; Kim YS
Oncol Res; 1993; 5(9):347-56. PubMed ID: 7518709
[TBL] [Abstract][Full Text] [Related]
36. Tumour markers in pancreatic cancer.
Haglund C; Kuusela P; Roberts PJ
Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
[TBL] [Abstract][Full Text] [Related]
37. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer.
Nishida K; Miyagawa H; Yoshikawa T; Kondo M
Oncology; 1988; 45(3):166-71. PubMed ID: 3163417
[TBL] [Abstract][Full Text] [Related]
38. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Heptner G; Domschke S; Schneider MU; Domschke W
Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
[TBL] [Abstract][Full Text] [Related]
39. [Attention to CA 19.9 in alcoholics. Apropos of a case].
Giovannini M; Penalvert F; Maillot A; Escoffier JM; Botta D; Gauthier A
Ann Gastroenterol Hepatol (Paris); 1987 Dec; 23(7):393. PubMed ID: 3481241
[No Abstract] [Full Text] [Related]
40. [Cancer-associated carbohydrate antigens available for serum diagnosis].
Sawabu N; Takemori Y; Satomura Y; Watanabe H; Kawakami H; Hattori N
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1091-101. PubMed ID: 2898921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
